onvansertib + FOLFIRI + bevacizumab

**Onvansertib + FOLFIRI + bevacizumab** is a combination drug regimen under investigation for metastatic colorectal cancer and potentially other advanced gastrointestinal cancers. It includes: - **Onvansertib**, a small molecule inhibitor of Polo-like kinase 1 (PLK1), which disrupts cell cycle progression, leading to apoptosis in cancer cells. - **FOLFIRI** (folinic acid, fluorouracil, irinotecan) is a standard chemotherapy regimen: - *Folinic acid* (leucovorin) potentiates fluorouracil activity by increasing its binding to target enzymes. - *Fluorouracil (5-FU)* is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death. - *Irinotecan* inhibits topoisomerase I, blocking DNA replication. - **Bevacizumab** is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth[2][6]. This combination is designed to target tumor cells with multiple mechanisms: cytotoxicity, cell cycle inhibition, and blockade of tumor blood supply. Clinical use focuses on metastatic colorectal cancer and studies are ongoing for other gastrointestinal malignancies[1][2][6].

Other names

FOLFIRIfolinic acid + fluorouracil + irinotecan